

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
WO 01/21645 A2(51) International Patent Classification<sup>7</sup>: C07K 14/00

(74) Agent: HARRISON GODDARD FOOTE; Tower House, Merriam Way, Leeds LS2 8PA (GB).

(21) International Application Number: PCT/GB00/03568

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
GB9921938.8 17 September 1999 (17.09.1999) GB

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): THE UNIVERSITY OF YORK [GB/GB]; Heslington Hall, York YO10 5DD (GB).

## Published:

— Without international search report and to be republished upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANTSON, Alfred [GB/GB]; Department of Chemistry, University of York, York YO10 5DD (GB); MAITLAND, Norman [GB/GB]; Department of Biology, University of York, York YO10 5DD (GB).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGET FOR ANTIVIRAL THERAPY

(57) Abstract: A crystallised molecular complex of an E2 N-terminal module (E2NT) dimer protein or homologue thereof, that comprises residues vital for viral transcription and/or replication. The invention also provides for the use of the dimer protein and interactions at its dimerisation surface in rationalised antiviral drug design.

WO 01/21645 A2